SALT LAKE CITY, UT / ACCESSWIRE / October 31, 2023 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on January 3, 2024 to shareholders of record at the close of business on December 15, 2023. This is a 1.7% increase over the prior regular quarterly cash dividend.
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.
Contact:
Brian Koopman
(801) 566-1200
| Last Trade: | US$55.52 |
| Daily Change: | -0.50 -0.89 |
| Daily Volume: | 19,281 |
| Market Cap: | US$180.440M |
November 05, 2024 October 29, 2024 July 25, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
